Dual and triple antithrombotic therapies: current patterns of practice and controversies

Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percu-taneous coronary intervention (PCI). Despite low-quality evidence, triple antithrombotic therapy involving acetylsalicylic acid, clopidogrel, and warfarin or non-vitamin K antagonist oral anticoagulant (NOAC) has been recommended in patients with concomitant atrial fibrillation undergoing PCI, who require long-term oral …